PF-Atlas › Clinical Trials › NCT00650091

Evaluating the Effectiveness of Prednisone, Azathioprine, and N-acetylcysteine in Patients With IPF

N-acetylcysteine · Phase 3

Registry ID
NCT00650091
Phase
Phase 3
Status
Completed
Drug / intervention
N-acetylcysteine (NAC)
Sponsor
Duke University
Start
2009-10
Enrollment
264
Locations
26

About this trial

Idiopathic pulmonary fibrosis (IPF) is a long-term lung disease that affects an individual's ability to breathe. In this randomized, double-blind, placebo-controlled trial, we assigned patients with idiopathic pulmonary fibrosis who had mild-to-moderate lung-function impairment to one of three groups - receiving a combination of prednisone, azathioprine, and NAC (combination therapy), NAC alone, or placebo - in a 1:1:1 ratio.

View NCT00650091 on ClinicalTrials.gov →

Explore related

All N-acetylcysteine trialsAll IPF trials

Related trials

N-acetylcysteine — NCT04155632N-acetylcysteine — NCT02088216N-acetylcysteine — NCT03956888
Medical disclaimer. This page summarizes public trial data for NCT00650091 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.